

Ad hoc Announcement Pursuant to § 15 WpHG (German Securities Trading Act):

Epigenomics AG: Notice of Loss pursuant to § 92 par. 1 AktG

Not for distribution in the United States

Berlin, Germany, December 21, 2012 – The Executive Board of Epigenomics AG (ISIN: E000A1K0516) notifies that during the preparation of the annual financial statements pursuant to German GAAP (HGB) accounting, according to its best judgment a cumulative loss of more than half of the nominal share capital of the company has been incurred. This is mainly attributable to budgeted losses from regular business operations but as well to higher than expected expenses in connection with the recently completed clinical study.

The Executive Board is actively reviewing different measures to compensate for the loss of half of the nominal share capital. The planned rights issue in January 2013 as announced previously on December 20, 2012 is part of the measures, which aim at improving the Company's equity and liquidity.

Pursuant to Sec. 92 par. 1 German Stock Corporation Act ("Aktiengesetz"), a loss amounting to half of the nominal share capital triggers the statutory obligation to summon a general meeting of shareholders without undue delay. The Executive Board will therefore invite to an extraordinary general meeting in due course. In this meeting, the Executive Board will notify the loss of half of the nominal share capital and outline the situation of the company. An invitation including an agenda to the extraordinary general meeting will be provided in due time and form.

- End of Ad hoc -

Contact Epigenomics AG
Antje Zeise CIRO Manager IR PR Epigenomics AG Phone: +49 (0) 30 24345 386 ir@epigenomics.com www.epigenomics.com

Legal disclaimers. This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update

epigenomics

any forward-looking statements contained herein as a result of new information, future events or otherwise.